Phase IIA Study in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the effects of AZD 2624 in patients with schizophrenia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Females of non-childbearing potential

• Diagnosis of Schizophrenia

Exclusion Criteria:

• Clinically relevant disease and /or abnormalities.

• Alcohol or substance abuse not in remission

• Enrollment in another investigational study within 30 days